Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report released on Monday. The firm set a “hold” rating on the stock.

Other equities analysts also recently issued research reports about the stock. Northland Securities reiterated a “market perform” rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a report on Thursday. Northland Capmk downgraded shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday. Brookline Capital Management reaffirmed a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday. Finally, HC Wainwright dropped their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Oncternal Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $20.00.

Oncternal Therapeutics Stock Down 14.1 %

Shares of Oncternal Therapeutics stock opened at $1.46 on Monday. Oncternal Therapeutics has a 52 week low of $1.32 and a 52 week high of $13.14. The company has a 50 day moving average price of $5.37 and a 200 day moving average price of $7.45. The firm has a market capitalization of $4.32 million, a P/E ratio of -0.12 and a beta of 1.39.

Oncternal Therapeutics (NASDAQ:ONCT) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, topping the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. The company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.24 million. During the same quarter in the prior year, the company earned ($3.00) EPS. As a group, research analysts anticipate that Oncternal Therapeutics will post -11.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Quantum Private Wealth LLC bought a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned approximately 0.94% of Oncternal Therapeutics at the end of the most recent reporting period. 16.05% of the stock is currently owned by institutional investors.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.